Pharma Reviews: SPARC licenses commercialisation rights of anti-epileptic drug to Tripoint Therapeutics

New Delhi: Sun Pharma Advanced Research Company (SPARC) on ... Drug User Fee Act) fees for Elepsia XR 1,000 mg and Elepsia XR 1,500 mg.
Read more: SPARC licenses commercialisation rights of anti-epileptic drug to Tripoint Therapeutics